C2RS34:BVMF
CRISPR Therapeutics AG
R$35.80
arrow_downward
-2.27%(-0.83) 1D
Sep 3, 10:56:00 AM GMT-3 · BRL
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for C2RS34...
Open
R$35.80
High
R$35.80
Low
R$35.80
Mkt. cap
5.43B
Avg. vol.
48.00
Volume
20.00
52-wk high
R$52.15
52-wk low
R$29.91
Shares outstanding
96.69M
No. of employees
393
Open
R$35.80
High
R$35.80
Low
R$35.80
Mkt. cap
5.43B
Avg. vol.
48.00
Volume
20.00
52-wk high
R$52.15
52-wk low
R$29.91
Shares outstanding
96.69M
No. of employees
393
News stories
From web sources and news partners
MarketBeat
·
3 days ago
CRISPR Therapeutics (NASDAQ:CRSP) Earns Buy Rating from Needham & Company LLC
Investing.com
·
3 days ago
H.C. Wainwright reiterates CRISPR Therapeutics stock rating at buy
Investing.com
·
3 days ago
Citizens reiterates CRISPR Therapeutics stock rating on gene therapy data
Profile
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
About CRISPR Therapeutics AG
CEOSamarth Kulkarni
Employees393
Founded2013
HeadquartersZug, Zug, Switzerland
SectorBiotechnology
Websitecrisprtx.com